| abstract |
Claim 1: A glucagon receptor agonist compound, characterized in that it comprises the formula: YX¹QGTFX²SDYSKYLDX³KKAX⁴EFVX⁵WLLEX⁶X⁷ wherein X¹ is Aib; X² is T; X³ is Aib; X⁴ is K which was chemically modified by conjugation to the e-amino group of the side chain of K with ([2- (2-amino-ethoxy) -ethoxy] -acetyl) ₂- (gGlu) ₐ-CO- (CH₂) ᵇ-CO₂H, where a is 1 and b is 18; X⁵ is A; X⁶ is E; and X⁷ is absent; (SEQ ID No. 12); or a pharmaceutically acceptable salt thereof. Claim 5: A method of treating fatty liver, characterized in that it comprises administering to an animal in need thereof, an effective amount of the glucagon receptor agonist according to any one of claims 1-4. Claim 9: A pharmaceutical composition, characterized in that it comprises the glucagon receptor agonist according to any one of claims 1-4 and a pharmaceutically acceptable carrier, diluent, or excipient. |